Evidence map›Paper›PMID 40091958›Full record

ReviewCureus2025

Cannabinoid Hyperemesis Syndrome: A Rising Complication.

Saar Peles, Roy Khalife, Anthony Magliocco

Abstract readReview
In one paragraph

Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Cannabinoid tolerance relies on CBProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Saar PelesGastrointestinal Oncology, University of Central Florida College of Medicine, Orlando, USA.
Roy KhalifeGenetics, Protean Biodiagnostics, Orlando, USA.
Anthony MaglioccoPathology, University of Central Florida College of Medicine, Orlando, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cannabis, commonly known as marijuana, is a psychoactive plant that has been used for both medicinal and recreational purposes for centuries. It contains over 100 biologically active compounds known as cannabinoids, the most notable of which are tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is responsible for the euphoric and hallucinogenic effects associated with cannabis use, while CBD is often utilized for its potential therapeutic benefits, such as pain relief and anti-inflammatory properties. Despite its widespread reputation for alleviating nausea and stimulating appetite, chronic cannabis use has been linked to a paradoxical condition known as cannabinoid hyperemesis syndrome (CHS). CHS is a disorder that paradoxically causes abdominal pain, nausea, and uncontrollable vomiting in long-term cannabis users rather than alleviating pain and reducing nausea. Misdiagnosis of this condition is extremely common, and it is often confused with cyclic vomiting syndrome (CVS). The underlying pathogenesis of CHS is not completely understood, though several mechanisms have been proposed. Although considered rare, there has been a steady increase in CHS diagnoses in the Emergency Department (ED). This article summarizes the symptoms, pathogenesis, treatments for CHS, and differential diagnoses to further increase our understanding of this condition.

Indexed as

cannabinoid hyperemesis syndrome (chs)cannabis usecyp systememergency medical servicesubstance-induced disorders

Identifiers

PMID40091958
PMCPMC11910202

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.